| Abstrakt: |
A study conducted by researchers from the University of Texas MD Anderson Cancer Center in Houston, Texas, examined the use of the hypomethylating agent azacitidine (AZA) in patients with acute myeloid leukemia (AML) who were ineligible for intensive induction chemotherapy (IC) or stem cell transplant. The study evaluated the efficacy and safety of combining AZA with the oral pan-HDAC inhibitor pracinostat in adult patients with newly diagnosed AML. However, the study did not show a benefit of adding pracinostat to AZA in elderly patients unfit for IC. The research was supported by Helsinn Healthcare and has been peer-reviewed. [Extracted from the article] |
